Through these initiatives, Thermo Fisher Scientific continues to lead innovations in science and healthcare, addressing critical challenges and improving global health outcomes
Thermo Fisher Scientific, a global leader in serving science, has made significant strides in 2024 with new initiatives, product launches, and collaborations to advance healthcare, sustainability, and precision science.
FDA Approvals and Companion Diagnostics
Thermo Fisher received FDA approval for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic for identifying patients eligible for Servier Pharmaceuticals’ VORANIGO (vorasidenib) tablets. This first targeted therapy for Grade 2 IDH-mutant glioma provides a critical care pathway for patients with limited treatment options.
Advanced Instruments and Sustainable Solutions
- Microscopy Innovations: The Thermo Scientific Iliad (S)TEM was unveiled at the European Microscopy Congress 2024 in Copenhagen, Denmark. This integrated analytical solution enables atomic-level insights into modern materials.
- Sustainable Packaging: Transitioning to ambient temperature shipping for 125,000 Invitrogen antibodies, Thermo Fisher reduced packaging waste, aligning with its sustainability goals.
- Innovative ICP-MS Systems: The new iCAP MX Series simplifies trace element analysis for various industries, improving accuracy and efficiency.
Expanding Research and Clinical Support
- CorEvitas Adolescent AD Registry: Addressing real-world evidence gaps, this registry expands beyond North America to study treatments for adolescent atopic dermatitis.
- OSD Footprint Expansion: A $22-million investment enhanced capabilities at sites in Cincinnati, Ohio, and Bend, Oregon, supporting early drug development.
- Global Laboratory Services: A new bioanalytical lab in Gothenburg, Sweden, expands advanced lab services for pharmaceutical development.
Grants, Recognitions, and Partnerships
- Oncomine Clinical Research Grants: Thermo Fisher recognized oncology research efforts globally, fostering advancements in precision medicine.
- R&D 100 Awards: Thermo Fisher’s Orbitrap Astral Mass Spectrometer earned recognition as a disruptive innovation in mass spectrometry.
- Collaborations: Partnerships, such as with Bayer AG, aim to develop NGS-based companion diagnostics for precision cancer therapies.
Expanding Manufacturing and Laboratory Innovations
- RNA Manufacturing: GMP approval at the Monza, Italy site supports RNA-based therapies for complex conditions.
- Ultra-Low Temperature Freezers: The TSX Universal Series combines performance with sustainability for advanced laboratory workflows.
- Automated Cell Therapy Solutions: The Gibco CTS Cellmation Software streamlines manufacturing processes, accelerating the delivery of cell therapies.
Groundbreaking Genomic and Biologics Solutions
- PangenomiX Array Launch: Designed for population-scale disease studies, this array offers extensive genetic coverage, reflecting global diversity.
- Biobased Films for Biologics: Transitioning to plant-based materials for bioprocessing containers reduces greenhouse gas emissions.
Through these initiatives, Thermo Fisher Scientific continues to lead innovations in science and healthcare, addressing critical challenges and improving global health outcomes.
